Total trials
115
Active
14
Phase 3
15
Total enrollment
155,962
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Levofloxacin | — | — | — | — | — | 2 | |
| Prednisone | — | — | — | — | — | 2 | |
| Rifampin | — | — | — | — | — | 1 | |
| Rifampicin, Pyrazinamide, Ethambutol and Isoniazid | — | — | — | — | — | 1 | |
| Atorvastatin 40mg | — | — | — | — | — | 1 | |
| high dose Rifampicin | — | — | — | — | — | 2 |
Next readouts
- 2025-09-15
- 2025-09-30
- 2025-12-15
Top conditions
- Tuberculosis20
- HIV9
- HIV Infections6
- Malaria5
- Hiv4
- Obesity3
- Chronic Pain2
- Central Sensitisation2
Frequently asked questions about University of Cape Town
- How many clinical trials does University of Cape Town have on ClinicalTrials.gov?
- University of Cape Town is listed as the lead sponsor on 115 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Cape Town's trials are in Phase 3?
- 15 of University of Cape Town's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does University of Cape Town focus on?
- University of Cape Town's most-studied conditions on ClinicalTrials.gov are Tuberculosis, HIV, HIV Infections, Malaria, Hiv.
- When are University of Cape Town's next clinical trial readouts?
- University of Cape Town has 3 upcoming primary-completion readouts tracked here; the soonest is “High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis”, expected around 2025-09-15.